TRIB Trinity Biotech: שווי פעילות לרווח לפני ריבית, מסים ופחת

Trinity Biotech plc (TRIB) generates revenue through the supply of diagnostic systems, where equipment sales guarantee recurring income from the sale of consumables. This EV/EBITDA chart reflects a current multiple of 0.00. The business relies on steady demand for the detection of critical pathologies, establishing the company as a defensive asset with revenue secured by multi-year agreements with medical centers.

This multiple compares the total enterprise value, including debt, with operating profit before taxes and depreciation, allowing for an assessment of the real value of assets relative to their ability to generate cash flow. By analyzing the change in the EV/EBITDA value over time, a conservative investor confirms the stability of Trinity Biotech plc (TRIB), whose operations in the global diagnostics sector under the protection of European law minimize risks during long-term capital planning.